Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 5, 2010, Pages 665-669

  Krasznai, Zoárd Tibor ^a   Tóth, Ágnes ^a   Mikecz, Pál ^a   Fodor, Zoltán ^a   Szabó, Gábor ^a   Galuska, László ^a   Hernádi, Zoltán ^a   Goda, Katalin ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

18FDG; 99mTc MIBI; Multidrug resistance; P glycoprotein; UIC2 monoclonal antibody

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY UIC2; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RHODAMINE 123; UNCLASSIFIED DRUG; VALSPODAR;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN A2780; CELL STRAIN A2780AD; CONTROLLED STUDY; DATA ANALYSIS; DRUG TRANSPORT; DRUG UPTAKE; FLOW CYTOMETRY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RADIOTRACER UPTAKE; TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CYCLOSPORINE; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN BINDING; RHODAMINE 123; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED;

EID: 78349307009     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.09.009     Document Type: Article

References (32)

1. Chen W.S., Luker K.E., Dahlheimer J.L., Pica C.M., Luker G.D., Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem. Pharmacol. 2000, 60:413-426.
2. Direcks W.G., Berndsen S.C., Proost N., Peters G.J., Balzarini J., Spreeuwenberg M.D., Lammertsma A.A., Molthoff C.F. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br. J. Cancer 2008, 99:481-487.
3. Fojo T., Coley H.M. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin. Breast Cancer 2007, 7:749-756.
4. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug. Deliv. 2004, 1:27-42.
5. Goda K., Fenyvesi F., Bacsó Z., Nagy H., Márián T., Megyeri A., Krasznai Z., Juhász I., Vecsernyés M., Szabó G. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J. Pharmacol. Exp. Ther. 2007, 320:81-88.
6. Goda K., Bacsó Z., Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr. Cancer Drug Targets 2009, 9:281-297.
7. Hamacher K., Coenen H.H., Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 1986, 27:235-238.
8. Higashi K., Ueda Y., Ikeda R., Kodama Y., Guo J., Matsunari I., Oguchi M., Tonami H., Katsuda S., Yamamoto I. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl. Med. Commun. 2004, 25:19-27.
9. Kannan P., John C., Zoghbi S.S., Halldin C., Gottesman M.M., Innis R.B., Hall M.D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 2009, 86:368-377.
10. Kostakoglu L., Ruacan S., Ergün E.L., Sayek I., Elahi N., Bekdik C.F. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J. Nucl. Med. 1998, 39:1021-1026.
11. Krasznai Z.T., Péli-Szabó J., Németh E., Balkay L., Szabó G., Goda K., Galuska L., Trón L., Major T., Hernádi Z. Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells. Eur. J. Pharm. Sci. 2006, 28:249-256.
12. 99mTc-labeled sestamibi and tetrofosmin. Nucl. Med. Biol. 2005, 32:573-583.
13. Louie K.G., Hamilton T.C., Winker M.A., Behrens B.C., Tsuruo T., Klecker R.W., McKoy W.M., Grotzinger K.R., Myers C.E., Young R.C., et al. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem. Pharmacol. 1986, 35:467-472.
14. Maki N., Hafkemeyer P., Dey S. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J. Biol. Chem. 2003, 278:18132-18139.
15. Mankoff D.A., Bellon J.R. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin. Radiat. Oncol. 2001, 11:16-27.
16. Márián T., Szabó G., Goda K., Nagy H., Szincsák N., Juhász I., Galuska L., Balkay L., Mikecz P., Trón L., Krasznai Z. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1147-1154.
17. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 1999, 128:403-411.
18. Mechetner E.B., Roninson I.B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:5824-5828.
19. Mechetner E.B., Schott B., Morse S.B., Stein W., Druley T., Davis K.A., Tsuruo T., Roninson I.B. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12908-12913.
20. Nagy H., Goda K., Arceci R., Cianfriglia M., Mechetner E.B., Szabó G. P-glycoprotein conformational changes detected by antibody competition. Eur. J. Biochem. 2001, 268:2416-2420.
21. Nagy H., Goda K., Fenyvesi F., Bacsó Z., Szilasi M., Kappelmayer J., Lustyik G., Cianfriglia M., Szabó G. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem. Biophys. Res. Commun. 2004, 315:942-949.
22. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., Mazière B. FDG accumulation and tumor biology. Nucl. Med. Biol. 1998, 25:317-322.
23. Polgár O., Bates S.E. ABC transporters in the balance: is there a role in multidrug resistance?. Biochem. Soc. Trans. 2005, 33:241-245.
24. Rohren E.M., Turkington T.G., Coleman R.E. Clinical applications of PET in oncology. Radiology 2004, 231:305-320.
25. Saeki T., Ueda K., Tanigawara Y., Hori R., Kamano T. Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem. 1993, 268:6077-6080.
26. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1997, 251:252-261.
27. Seelig A., Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 2000, 12:31-40.
28. 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int. J. Oncol. 2009, 34:1303-1312.
29. Wahl L.R. Targeting glucose transporters for tumor imaging: " sweet" idea, " sour" result. J. Nucl. Med. 1996, 37:1038-1041.
30. Watanabe T., Naito M., Kokubu N., Tsuruo T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives and MRK-16 antibodies. J. Natl. Cancer Inst. 1997, 89:512-518.
31. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J. Nucl. Med. 2005, 46:983-995.
32. Yamada K., Brink I., Engelhardt R. Factors influencing [F-18] 2-fluoro-2-deoxy-d-glucose (F-18 FDG) accumulation in melanoma cells: Is FDG a substrate of multidrug resistance (MDR)?. J. Dermatol. 2005, 32:335-345.